{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T14:42:47Z","timestamp":1781880167379,"version":"3.54.5"},"reference-count":13,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annales de Dermatologie et de V\u00e9n\u00e9r\u00e9ologie"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.annder.2024.103304","type":"journal-article","created":{"date-parts":[[2024,8,27]],"date-time":"2024-08-27T21:47:01Z","timestamp":1724795221000},"page":"103304","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Pemigatinib-associated calcinosis cutis: First case of complete regression with continued phosphate chelator therapy"],"prefix":"10.1016","volume":"151","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-3796-1829","authenticated-orcid":false,"given":"P.-L.","family":"Chantreau","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Lebidre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Tallegas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7709-9844","authenticated-orcid":false,"given":"F.","family":"Dujardin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Samimi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2201-6914","authenticated-orcid":false,"given":"T.","family":"Kervarrec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.annder.2024.103304_b0005","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/j.ad.2015.09.001","article-title":"Calcinosis cutis and calciphylaxis","volume":"106","author":"Jim\u00e9nez-Gallo","year":"2015","journal-title":"Actas Dermosifiliogr"},{"key":"10.1016\/j.annder.2024.103304_b0010","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1111\/cup.13319","article-title":"Calcinosis cutis dermatologic toxicity associated with fibroblast growth factor receptor inhibitor for the treatment of Wilms tumor","volume":"45","author":"Arudra","year":"2018","journal-title":"J Cutan Pathol"},{"key":"10.1016\/j.annder.2024.103304_b0015","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1001\/jamadermatol.2018.4070","article-title":"Metastatic calcinosis cutis associated with a selective FGFR inhibitor","volume":"155","author":"Carr","year":"2019","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.annder.2024.103304_b0020","doi-asserted-by":"crossref","first-page":"adv00079","DOI":"10.2340\/00015555-3438","article-title":"Metastatic calcinosis cutis secondary to selective fibroblast growth factor receptor inhibitor: rapid and complete regression after blood phosphate normalization and drug withdrawal","volume":"100","author":"Lopez-Castillo","year":"2020","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.annder.2024.103304_b0025","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.aace.2022.07.001","article-title":"Hyperphosphatemic tumoral calcinosis with pemigatinib use","volume":"8","author":"Puar","year":"2022","journal-title":"AACE Clin Case Rep"},{"key":"10.1016\/j.annder.2024.103304_b0030","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.jdcr.2022.10.040","article-title":"Fibroblast growth factor receptor inhibitor therapy induced calcinosis cutis treated with sodium thiosulfate","volume":"31","author":"Qian","year":"2023","journal-title":"JAAD Case Rep"},{"key":"10.1016\/j.annder.2024.103304_b0035","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1038\/nrc2780","article-title":"Fibroblast growth factor signalling: from development to cancer","volume":"10","author":"Turner","year":"2010","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.annder.2024.103304_b0040","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1158\/1078-0432.CCR-14-3212","article-title":"The FGFR landscape in cancer: analysis of 4,853 tumors by next-generation sequencing","volume":"22","author":"Helsten","year":"2016","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.annder.2024.103304_b0045","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1634\/theoncologist.2013-0352","article-title":"New routes to targeted therapy of intrahepatic cholangiocarcinomas revealed by next-generation sequencing","volume":"19","author":"Ross","year":"2014","journal-title":"Oncologist"},{"issue":"5","key":"10.1016\/j.annder.2024.103304_b0050","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/S1470-2045(20)30109-1","article-title":"Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study","volume":"21","author":"Abou-Alfa","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.annder.2024.103304_b0055","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1007\/s40265-020-01330-y","article-title":"Pemigatinib: first approval","volume":"80","author":"Hoy","year":"2020","journal-title":"Drugs"},{"key":"10.1016\/j.annder.2024.103304_b0060","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1080\/01926230590961845","article-title":"Cartilage dysplasia and tissue mineralization in the rat following administration of a FGF receptor tyrosine kinase inhibitor","volume":"33","author":"Brown","year":"2005","journal-title":"Toxicol Pathol"},{"key":"10.1016\/j.annder.2024.103304_b0065","doi-asserted-by":"crossref","first-page":"e316","DOI":"10.1002\/onco.13552","article-title":"Dermatologic adverse events associated with selective fibroblast growth factor receptor inhibitors: overview, prevention, and management guidelines","volume":"26","author":"Lacouture","year":"2021","journal-title":"Oncologist"}],"container-title":["Annales de Dermatologie et de V\u00e9n\u00e9r\u00e9ologie"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0151963824000607?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0151963824000607?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,9,19]],"date-time":"2024-09-19T22:49:41Z","timestamp":1726786181000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0151963824000607"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":13,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["S0151963824000607"],"URL":"https:\/\/doi.org\/10.1016\/j.annder.2024.103304","relation":{},"ISSN":["0151-9638"],"issn-type":[{"value":"0151-9638","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pemigatinib-associated calcinosis cutis: First case of complete regression with continued phosphate chelator therapy","name":"articletitle","label":"Article Title"},{"value":"Annales de Dermatologie et de V\u00e9n\u00e9r\u00e9ologie","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.annder.2024.103304","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"103304"}}